Entinostat

The addition of entinostat to exemestane improved PFS for patients with hormone receptor-positive, HER2-negative advanced breast cancer, according to randomized phase 3 study results presented at San Antonio Breast Cancer Symposium.

ATLANTA — The combination of the histone deacetylase inhibitor entinostat and the anti-PD-1 inhibitor pembrolizumab induced clinical responses and appeared well-tolerated among patients with melanoma that progressed on prior anti-PD-1 treatment, according to results from the single-arm ENCORE 601 phase 1b/phase 2 clinical trial presented at American Association of Cancer Research Annual Meeting.